These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 1384050)

  • 21. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes.
    Llorente M; Sánchez-Palomino S; Mañes S; Lucas P; Kremer L; De Alborán IM; Torán JL; Alcamí J; Del Real G; Martínez-A C
    Scand J Immunol; 1999 Sep; 50(3):270-9. PubMed ID: 10447936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.
    Torán JL; Sánchez-Pulido L; Kremer L; del Real G; Valencia A; Martínez-A C
    Eur J Immunol; 2001 Jan; 31(1):128-37. PubMed ID: 11169446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
    Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
    Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.
    Yang WP; Green K; Pinz-Sweeney S; Briones AT; Burton DR; Barbas CF
    J Mol Biol; 1995 Dec; 254(3):392-403. PubMed ID: 7490758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus.
    de Carvalho Nicacio C; Lundkvist A; Sjölander KB; Plyusnin A; Salonen EM; Björling E
    J Med Virol; 2000 Apr; 60(4):446-54. PubMed ID: 10686029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of HIV-1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long-term non-progressor HIV-1-infected individual.
    Torán JL; Kremer L; Sánchez-Pulido L; de Alborán IM; del Real G; Llorente M; Valencia A; de Mon MA; Martínez-A C
    Eur J Immunol; 1999 Sep; 29(9):2666-75. PubMed ID: 10508241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gp120.
    Stura EA; Stanfield RL; Fieser GG; Silver S; Roguska M; Hincapie LM; Simmerman HK; Profy AT; Wilson IA
    Proteins; 1992 Dec; 14(4):499-508. PubMed ID: 1438187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction of human Fab (gamma1/kappa) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus.
    Arakawa M; Yamashiro T; Uechi G; Tadano M; Nishizono A
    Microbiol Immunol; 2007; 51(6):617-25. PubMed ID: 17579273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain.
    Liang M; Mahler M; Koch J; Ji Y; Li D; Schmaljohn C; Bautz EK
    J Med Virol; 2003 Jan; 69(1):99-107. PubMed ID: 12436484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells.
    Condra JH; Sardana VV; Tomassini JE; Schlabach AJ; Davies ME; Lineberger DW; Graham DJ; Gotlib L; Colonno RJ
    J Biol Chem; 1990 Feb; 265(4):2292-5. PubMed ID: 2153680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recombinant Fab neutralizes dengue virus in vitro.
    Thullier P; Lafaye P; Mégret F; Deubel V; Jouan A; Mazié JC
    J Biotechnol; 1999 Apr; 69(2-3):183-90. PubMed ID: 10361725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display.
    Björling E; von Garrelts E; Mörner A; Ehnlund M; Persson MAA
    J Gen Virol; 1999 Aug; 80 ( Pt 8)():1987-1993. PubMed ID: 10466795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4.
    Bachelder RE; Bilancieri J; Lin W; Letvin NL
    J Virol; 1995 Sep; 69(9):5734-42. PubMed ID: 7637018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A binary plasmid system for shuffling combinatorial antibody libraries.
    Collet TA; Roben P; O'Kennedy R; Barbas CF; Burton DR; Lerner RA
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10026-30. PubMed ID: 1438192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cloning and characterization of human recombinant antibody Fab fragments specific for types 1 and 2 herpes simplex virus.
    Cattani P; Plaisant P; Manzara S; Capodicasa N; Burioni R; Rossolini GM; Satta G
    New Microbiol; 1995 Apr; 18(2):135-42. PubMed ID: 7603340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human antibodies to HIV-1 by recombinant DNA methods.
    Burton DR; Barbas CF
    Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
    [No Abstract]   [Full Text] [Related]  

  • 39. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.
    Sharon M; Görlach M; Levy R; Hayek Y; Anglister J
    Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Kliks SC; Shioda T; Haigwood NL; Levy JA
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11518-22. PubMed ID: 7505441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.